Halozyme Therapeutics $1.5B Debt Financing with The Bank of New York Mellon Trust Company, N.A.
Halozyme Therapeutics completed the sale of $1.5 billion in 1.50% Convertible Senior Notes due 2033, which included a $200 million overallotment option exercised by initial purchasers. The company used the proceeds to fund capped call transactions and to repurchase approximately $652.5 million of its existing 0.25% notes due 2027 and 1.00% notes due 2028.
Halozyme Therapeutics priced an upsized private offering of $1.3 billion in 1.50% convertible senior notes due 2033, with an additional $200 million option granted to initial purchasers. The company entered into capped call transactions to manage potential dilution, with an initial cap price representing a 90% premium over the current stock price. Proceeds are intended for general corporate purposes, which may include debt repayment or share repurchases.
Halozyme Therapeutics announced a proposed offering of $1.05 billion in convertible senior notes due 2033, with an additional $150 million overallotment option for initial purchasers. The company intends to use the proceeds to fund capped call transactions, repurchase a portion of its existing 0.25% notes due 2027 and 1.00% notes due 2028, and for general corporate purposes.